Shots:

• The two P-III POETYK PSO-1 and POETYK PSO-2 trials evaluating deucravacitinib (6mg- qd) vs PBO & Otezla (30mg- bid) @16wks. and vs Otezla @24wks. in 666 and 1-020 patients with the mod. to sev. plaque psoriasis respectively
• The trials met its co-1EPs & 2EPs i.e @16wks.- PASI 75 (58.7% and 53.6%) vs (12.7% and 9.4%)& (35.1% and 40.2%) and @24wks. (69.0% and 59.3%) vs (38.1% and 37.8%)- patients who achieved PASI 75- continued treatment with deucravacitinib (82.5% and 81.4%) and maintained it @52wks. respectively
• sPGA 0/1 response @16wks. (53.6% and 50.3%) vs (7.2% and 8.6%) & (32.1% and 34.3%) and @24wks (58.4% and 50.4%) vs (31.0% and 29.5%) respectively

  Ref: BMS | Image: BMS